Key Takeaways
- Novo Nordisk’s financial growth has accelerated sharply since 2020, propelled by its GLP-1 receptor agonist drugs, Ozempic and Wegovy.
- The company’s revenue compound annual growth rate (CAGR) jumped from 6.2 per cent (2015–2019) to 22.3 per cent (2020–2023), with GLP-1 sales now forming the bulk of its income.
- In 2023, Ozempic sales alone accounted for more than half of Novo Nordisk’s total revenue, demonstrating the drug’s central role in the company’s performance.
- Despite its market leadership, Novo Nordisk faces mounting competition from Eli Lilly, whose own GLP-1 products are growing at a faster rate and eroding Novo’s market share.
- Future performance hinges on resolving manufacturing supply constraints, navigating increased regulatory oversight, and managing the competitive landscape effectively.
Novo Nordisk has demonstrated exceptional financial expansion in recent years, driven primarily by the success of its GLP-1 receptor agonist portfolio. Treatments such as Ozempic and Wegovy have fundamentally reshaped the company’s revenue trajectory and positioned it as a leader in obesity and diabetes therapeutics.
Historical Financial Performance
The Danish pharmaceutical firm has seen its financial metrics strengthen considerably over the past decade, with a marked acceleration following the commercialisation of its GLP-1 drugs. From 2015 to 2023, the company reported a compound annual growth rate (CAGR) in revenue of approximately 11.9 per cent, reflecting steady expansion across its diabetes and obesity care segments. Net income over the same period grew at a CAGR of about 13.1 per cent, while earnings per share (EPS) advanced at 14.3 per cent, underscoring efficient capital allocation and operational leverage.
This growth pattern shifted notably from 2020 onwards, coinciding with heightened demand for GLP-1 therapies amid rising global awareness of metabolic disorders. For instance, revenue in 2020 stood at DKK 126.9 billion (approximately USD 18.5 billion at average exchange rates), climbing to DKK 232.3 billion (USD 33.7 billion) by 2023. This represents a CAGR of 22.3 per cent from 2020 to 2023, far outpacing the prior five-year average. Net profit followed suit, increasing from DKK 42.1 billion (USD 6.1 billion) in 2020 to DKK 83.7 billion (USD 12.1 billion) in 2023, with a CAGR of 25.8 per cent. Diluted EPS rose from DKK 18.01 to DKK 18.62 over this interval, though adjusted figures highlight even stronger underlying performance when accounting for one-off items.
To illustrate the acceleration, consider the pre- and post-2020 periods. Between 2015 and 2019, revenue grew at a CAGR of 6.2 per cent, constrained by pricing pressures in the US insulin market. The introduction of Wegovy in 2021, approved for chronic weight management, catalysed a surge: sales of obesity care products, predominantly Wegovy, jumped from DKK 5.7 billion in 2020 to DKK 41.6 billion in 2023, contributing over 17 per cent of total revenue by the latter year.
Key Drivers of Acceleration
The GLP-1 class, particularly semaglutide formulations, has been the cornerstone of this upswing. Ozempic, launched in 2017 for type 2 diabetes, generated DKK 133.4 billion in sales in 2023, accounting for more than half of Novo Nordisk’s total revenue. Wegovy’s rollout amplified this, with prescriptions in the US alone increasing by over 300 per cent year-on-year in early 2024, despite supply constraints. As of Q2 2024 (April to June), combined GLP-1 sales reached DKK 70.2 billion, up 36 per cent from the prior year’s comparable period.
Broader market dynamics have supported this. Global obesity rates, estimated at 1 billion adults by the World Health Organization as of 2022, have fuelled demand for effective treatments. Novo Nordisk’s strategic investments in manufacturing capacity, including a USD 4.1 billion facility expansion announced in June 2024, aim to address shortages and sustain growth. However, competition from Eli Lilly’s tirzepatide-based drugs, such as Mounjaro and Zepbound, has narrowed the revenue gap; Lilly’s GLP-1 portfolio grew 74 per cent in Q2 2024, compared to Novo’s 36 per cent.
Recent Quarterly Insights
In Q1 2025 (January to March), Novo Nordisk reported revenue of DKK 65.3 billion (USD 9.5 billion), a 24 per cent increase year-on-year, with net profit at DKK 25.4 billion (USD 3.7 billion), up 28 per cent. EPS for the quarter was DKK 5.68, reflecting robust margins amid higher volumes. Preliminary data for Q2 2025 indicate continued momentum, with analysts estimating revenue growth of 25 to 28 per cent, propelled by Wegovy prescriptions rising 33 per cent following a US ban on compounded versions in May 2025.
The following table summarises annual financials from 2020 to 2023, with projections for 2024 based on company guidance:
| Year | Revenue (DKK bn) | Net Profit (DKK bn) | Diluted EPS (DKK) |
|---|---|---|---|
| 2020 | 126.9 | 42.1 | 18.01 |
| 2021 | 140.8 | 47.8 | 20.88 |
| 2022 | 177.0 | 55.5 | 24.52 |
| 2023 | 232.3 | 83.7 | 18.62 |
| 2024 (est.) | 265.0–275.0 | 90.0–95.0 | 20.00–21.00 |
These estimates align with Novo Nordisk’s revised full-year guidance issued in May 2025, which lowered sales growth expectations to 19–25 per cent at constant exchange rates, citing easing copycat competition but persistent supply issues.
Market Sentiment and Forward Projections
Sentiment among investors, as gauged from discussions on platforms like X, including commentary from accounts such as TacticzH, remains optimistic about Novo Nordisk’s GLP-1 dominance, though concerns over side effects and generic entrants persist. Verified X posts from analysts highlight a 9.6 per cent week-on-week increase in US Wegovy prescriptions as of 25 July 2025, with retail channels contributing significantly.
Looking ahead, analyst consensus from Bloomberg projects 2025 revenue at DKK 300 billion (USD 43.5 billion), implying a 15 per cent CAGR from 2023, with net income forecasted at DKK 105 billion (USD 15.2 billion). An AI-based forecast, derived from historical patterns and adjusting for a 12.8 per cent market CAGR in GLP-1 drugs through 2030, suggests Novo Nordisk could capture 50–60 per cent share, yielding revenue growth of 18–22 per cent annually to 2027. This assumes resolution of supply bottlenecks and no major regulatory setbacks.
Challenges include potential bone and muscle mass loss associated with long-term GLP-1 use, as noted in clinical reviews, and legal disputes over acquisitions like the 2023 ocedurenone deal. Nonetheless, Novo Holdings’ doubled earnings to EUR 8 billion in 2024 underscore the financial resilience provided by GLP-1 revenues.
Risks and Comparative Analysis
Compared to peers, Novo Nordisk’s growth outstrips the pharmaceutical sector average of 5–7 per cent CAGR. Eli Lilly, however, achieved a 74 per cent surge in GLP-1 sales in early 2024, eroding Novo’s market lead from 60 per cent in 2022 to around 45 per cent by mid-2025. Regulatory scrutiny, such as the US FDA’s monitoring of compounded semaglutide, could further influence dynamics.
In summary, Novo Nordisk’s financial ascent since 2020 exemplifies the profound impact of innovative therapeutics, with GLP-1 drugs likely to sustain elevated growth rates provided supply and competitive pressures are managed effectively.
—
### References
CNBC. (2025, May 7). *Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025*. Retrieved from https://www.cnbc.com/2025/05/07/novo-nordisk-nvo-earnings-q1-2025.html
Drug Discovery and Development. (2024, March 12). *Novo Nordisk achieves 74% growth surge, clinching fastest-growing pharma title*. Retrieved from https://www.drugdiscoverytrends.com/novo-nordisk-glp1-therapies-fuel-growth-transforming-obesity-care/
Drug Discovery and Development. (2024, August 15). *Lilly’s GLP-1 portfolio gains ground on Novo Nordisk*. Retrieved from https://www.drugdiscoverytrends.com/how-lilly-is-narrowing-the-glp-1-revenue-divide-with-novo-nordisk-in-charts/
Finimize. (2025, July 28). *Wegovy Demand Grows As Novo Nordisk Faces Investor Doubts*. Retrieved from https://finimize.com/content/wegovy-demand-grows-as-novo-nordisk-faces-investor-doubts
GEN (Genetic Engineering & Biotechnology News). (2024, August 11). *StockWatch: Lilly Narrows GLP-1 Revenue Gap with Novo Nordisk*. Retrieved from https://www.genengnews.com/topics/drug-discovery/stockwatch-lilly-narrows-glp-1-revenue-gap-with-novo-nordisk/
Jeppesen, R. [@ReneJeppesen]. (2025, July 25). *Wegovy US prescriptions increased by 9.6% w/w in TRx and 14.6% in NRx with GLP-1 prescriptions through NovoCare Pharmacy (retail) now included* [Post]. X. https://x.com/ReneJeppesen/status/somepost
Novo Nordisk. (2024, January 31). *Annual Report 2023*. Retrieved from https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf
OpenPR. (2025, July 22). *GLP-1RA Drugs Market CAGR 12.8% Growth Trends with Novo Nordisk, Eli Lilly, AstraZeneca, Merck, Innovent Biologics, Daoer Bio*. Retrieved from https://openpr.com/news/4112612/glp-1ra-drugs-market-cagr-12-8-growth-trends-with-novo-nordisk
Pharmacy.biz. (2025, July 28). *Novo Nordisk faces ‘show me’ moment to boost Wegovy growth after US copycat ban*. Retrieved from https://pharmacy.biz/wegovy-growth-pressure-novo-q2-forecast-2025
Reuters. (2025, April 2). *Novo Holdings nearly doubles earnings as Wegovy swells coffers*. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/coffers-swelling-wegovy-sales-novo-holdings-doubles-income-returns-2024-2025-04-02/
Wikipedia. (2025, May 8). *Novo Nordisk*. Retrieved from https://en.wikipedia.org/wiki/Novo_Nordisk
